AXT's Geographic Reach Expands: Can It Drive More Revenue Growth?

AXT's first-half 2026 revenue diversification accelerated, with Europe revenue up 302.3% year over year and Asia-Pacific ex-China, Taiwan and Japan up 369.5%, supported by stronger InP demand and additional Chinese export approvals. China still represented 64% of first-half revenue, though management expects its share to normalize to 40%-60% as overseas capacity and supply agreements expand; North American sales remain limited by export restrictions. The 2026 revenue consensus is $217.6 million and EPS is projected at $0.86 versus a $0.41 loss in 2025, but competitive risks are rising as Coherent and Lumentum expand InP-based optical-connectivity capacity. AXTI has gained 1,467.8% over the past year and trades at a 32.76x forward P/E, well above the semiconductor-industry 12.73x multiple.

Analysis

AXTI’s investment case has shifted from an InP-cycle recovery to an execution-sensitive geographic and export-permit arbitrage. Incremental non-China sales can improve customer diversification and reduce the discount applied to concentrated China exposure, but small revenue bases make reported regional growth rates a poor indicator of durable demand. The key question for the next 1-3 quarters is whether mix diversification comes with higher utilization and gross-margin expansion, rather than merely rerouting constrained product through lower-margin channels.

The more consequential second-order risk is vertical integration by COHR and LITE. As larger optical-component vendors expand internal InP capacity, they can reduce merchant substrate purchases precisely when AXTI needs volume growth to absorb fixed costs; this is a structural risk over 6-18 months, not an immediate demand-collapse call. AXTI’s premium multiple leaves little room for a delay in qualification cycles, permit renewals, or a customer inventory correction after rapid optical-network buildouts. North American restrictions also cap access to the highest-value AI optical supply chain, limiting the valuation benefit from broad-based diversification.

Consensus appears to be extrapolating revenue recovery into an earnings normalization without adequately underwriting pricing. A cleaner revenue mix is positive only if contract terms demonstrate multi-quarter visibility and if InP wafer ASPs hold against captive supply additions. Watch the next report for gross margin, China mix, backlog/long-term agreement duration, and cash conversion; revenue growth without these confirmations should be treated as multiple-risk rather than a catalyst.

Key Decisions for Investors

• Do not chase AXTI after the momentum move; establish only a small tactical long on a post-earnings pullback if revenue guidance is raised and gross margin expands sequentially. Target a 3-6 month rerating only if management demonstrates diversified backlog; exit on a guidance cut or gross-margin decline despite revenue growth.
• Preferred relative-value expression: long COHR / short AXTI over 6-12 months. COHR’s internal capacity and broader system-level optical exposure should capture more value if AI connectivity demand persists, while AXTI remains exposed to merchant-wafer pricing; reassess if AXTI secures disclosed multi-year, take-or-pay supply agreements that materially improve volume visibility.
• For AXTI holders, use downside protection around the next earnings release rather than adding outright: the critical downside trigger is evidence that export approvals accelerated shipments but not sustainable order rates. A miss on gross margin or China concentration remaining near current levels would challenge the diversification thesis and could compress the premium earnings multiple.
• Monitor LITE and COHR capex, wafer-capacity commentary, and optical-component lead times quarterly. Rising captive production alongside easing transceiver lead times is the strongest falsifier for AXTI’s medium-term pricing and utilization assumptions.